PMID- 25454625
OWN - NLM
STAT- MEDLINE
DCOM- 20150730
LR  - 20221207
IS  - 1879-1166 (Electronic)
IS  - 0198-8859 (Linking)
VI  - 75
IP  - 12
DP  - 2014 Dec
TI  - Influence of glucose-lowering rate on CKMB and myoglobin serum levels in type-2 
      diabetes patients with coronary heart disease.
PG  - 1182-7
LID - S0198-8859(14)00471-6 [pii]
LID - 10.1016/j.humimm.2014.10.006 [doi]
AB  - OBJECTIVE: To analyze the level of creatine kinase isoenzyme (CKMB), myoglobin, 
      to explore the influence of different glucose-lowering rate on cardiac enzyme in 
      type 2 diabetes mellitus patients with coronary heart disease (T2DMC), to search 
      for the rational glucose-lowering rate. METHODS: A total number of 293 type 2 
      diabetic patients who were hospitalized in the First Affiliated Hospital of 
      Harbin Medical University from May 2008 to December 2009 were recruited. Two 
      groups were divided according to the coronary angiography. 142 subjects of type 2 
      diabetes mellitus (T2DM) and 151 subjects of T2DMC received intensive glucose 
      therapy. After CKMB and myoglobin being measured, variation and correlation 
      factors were evaluated. RESULTS: In T2DM group, the level of CKMB was 
      significantly lower at follow-up than that before intensive therapy. Then, we got 
      four subgroups according to the glucose-lowering rate. In T2DM group, when the 
      fasting or postprandial glucose-lowering rate was no more than 6 mmolL(-1)d(-1), 
      the level of CKMB and myoglobin were significantly lower than that before 
      intensive therapy (P<0.05). When the fasting glucose-lowering rate is faster than 
      6 mmolL(-1)d(-1), the level of CKMB is significantly higher after intensive 
      therapy than that before glucose-lowering (P<0.05). In T2DMC group, when the 
      fasting or postprandial glucose-lowering rate was not more than 4 mmolL(-1)d(-1), 
      the level of CKMB and myoglobin was significantly lower than that before 
      intensive therapy (P<0.05, P<0.01). When the fasting glucose-lowering rate was 
      faster than 4 mmolL(-1)d(-1), the level of CKMB and myoglobin was significantly 
      higher at follow-up than that before intensive therapy (P<0.05). Before intensive 
      therapy, high density lipoprotein cholesterol (HDL-C) has a negative linear 
      regression relationship with CKMB (P<0.01). Low density lipoprotein cholesterol 
      (LDL-C) and triglyceride (TG) and glycosylated hemoglobin A1c (HbA1c) have a 
      positive linear regression relationship with CKMB (P<0.05). HDL-C has a negative 
      linear regression relationship with myoglobin (P<0.01). LDL-C and TG have a 
      positive linear regression relationship with myoglobin (P<0.01). CONCLUSIONS: 
      T2DM patients, no matter with CHD or not, all have a rational fasting 
      glucose-lowering rate; the fasting glucose-lowering rate is more susceptible to 
      myocardial damage anticipation than the postprandial glucose-lowering rate.
CI  - Copyright (c) 2014 American Society for Histocompatibility and Immunogenetics. 
      Published by Elsevier Inc. All rights reserved.
FAU - Sun, Zhenjie
AU  - Sun Z
AD  - The First Clinical Medical School, Harbin Medical University, PR China.
FAU - Wu, Weihua
AU  - Wu W
AD  - The First Clinical Medical School, Harbin Medical University, PR China. 
      Electronic address: hydwwh@163.com.
FAU - Liu, Jiajia
AU  - Liu J
AD  - The First Clinical Medical School, Harbin Medical University, PR China.
FAU - Ma, Nan
AU  - Ma N
AD  - The First Clinical Medical School, Harbin Medical University, PR China.
FAU - Zheng, Zhaohui
AU  - Zheng Z
AD  - The First Clinical Medical School, Harbin Medical University, PR China.
FAU - Li, Qian
AU  - Li Q
AD  - The First Clinical Medical School, Harbin Medical University, PR China.
FAU - Wang, Mingli
AU  - Wang M
AD  - The First Clinical Medical School, Harbin Medical University, PR China.
FAU - Miao, Jiajing
AU  - Miao J
AD  - The First Clinical Medical School, Harbin Medical University, PR China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141013
PL  - United States
TA  - Hum Immunol
JT  - Human immunology
JID - 8010936
RN  - 0 (Blood Glucose)
RN  - 0 (Cholesterol, HDL)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Myoglobin)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - EC 2.7.3.2 (Creatine Kinase, MB Form)
SB  - IM
MH  - Adult
MH  - Blood Glucose/*analysis
MH  - Cholesterol, HDL/blood
MH  - Cholesterol, LDL/blood
MH  - Coronary Disease/*blood
MH  - Creatine Kinase, MB Form/*blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myoglobin/*blood
MH  - Triglycerides/blood
OTO - NOTNLM
OT  - Coronary heart disease
OT  - Creatine kinase isoenzyme
OT  - Glucose-lowering rate
OT  - Myoglobin
OT  - Type 2 diabetes mellitus
EDAT- 2014/12/03 06:00
MHDA- 2015/08/01 06:00
CRDT- 2014/12/03 06:00
PHST- 2013/12/19 00:00 [received]
PHST- 2014/10/08 00:00 [revised]
PHST- 2014/10/08 00:00 [accepted]
PHST- 2014/12/03 06:00 [entrez]
PHST- 2014/12/03 06:00 [pubmed]
PHST- 2015/08/01 06:00 [medline]
AID - S0198-8859(14)00471-6 [pii]
AID - 10.1016/j.humimm.2014.10.006 [doi]
PST - ppublish
SO  - Hum Immunol. 2014 Dec;75(12):1182-7. doi: 10.1016/j.humimm.2014.10.006. Epub 2014 
      Oct 13.